NEW YORK, Sept. 7, 2023 /PRNewswire/ -- The Wilson's disease drugs market size is expected to grow by USD 179.97 million from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of 6.32% during the forecast period, according to Technavio Research. North America is estimated to contribute 38% to the growth of the global market during the forecast period. As a result of favorable regulatory initiatives related to the approval of Wilson's disease drugs, drug developers are encouraged to explore new treatment options. The US is a major revenue contributor to the Wilson's disease WCD drugs market in this region. Thus, such factors are expected to drive the growth of the regional market during the forecast period. The market has been segmented by product (Chelators and Minerals), distribution channel (Retail pharmacies, Hospital pharmacies, and Online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW)). This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE PDF Sample Report
Company Profile:
ANI Pharmaceuticals Inc., Apotex Inc., AstraZeneca Plc, Bausch Health Co. Inc., Breckenridge Pharmaceutical Inc., Dr. Reddys Laboratories Ltd., Endo International Plc, Lupin Ltd., Merck and Co. Inc., Navinta LLC, Noblepharma Co. Ltd., Panacea Biotec Ltd., Recordati S.p.A, Sanofi, Taj Pharmaceutical Ltd., Teva Pharmaceutical Industries Ltd., and Tsumura and Co.
ANI Pharmaceuticals Inc. - The company offers Wilson's disease drugs such as ANI Pharmaceuticals Cuprimine. To gain access to more company profiles available with Technavio, buy the report!
- The market share growth by the chelators segment will be significant during the forecast period. The discovery of treatments to treat Wilson's disease has been a priority for the pharmaceutical industry and research organizations. The strengthening of the market for chelators will be driven by continuing research initiatives carried out by market players such as Bausch Recordati and Teva Pharmaceuticals, along with others on that market who are taking new technologies in addition to important government and private sector financial investment into Wilson's disease research. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Wilson's Disease Drugs Market: Market Dynamics
Key Driver
Increasing awareness among people for disease treatment is the key driver for the growth of the market. Various organizations, such as the Wilson Disease Association and the National Foundation for Rare Disorders, raise awareness about Wilson's disease. The New York-based Wilson's Disease Association is a voluntary organization that promotes the health of patients with Wilson's disease by providing up-to-date information about the disease, its symptoms, and its treatment. In addition, the Wilson Disease Association funds research and clinical trials on Wilson's disease. Hence, increasing awareness among individuals about the treatment of Wilson's disease will fuel the growth of the Wilson disease drugs market during the forecast period.
Leading Trend - The growing prevalence of chronic pain is a primary trend shaping the growth of the Wilson's disease drug market. Strategic alliances among market companies are a key trend in the Wilson's disease drugs market Identify key trends, drivers, and challenges in the market. Download to gain access to this information.
Related Reports:
The Antibacterial Drugs Market size is estimated to grow by USD 9,908.11 million at a CAGR of 4.21% between 2022 and 2027.
The global gastric cancer drugs market size is estimated to grow by USD 12,764.91 million at a CAGR of 14.85% between 2022 and 2027.
What are the key data covered in this Wilson's disease drugs market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the Wilson's disease drugs market between 2022 and 2027.
- Precise estimation of the Wilson's disease drugs market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the Wilson's disease drugs market across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of Wilson's disease drugs market companies.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Company Landscape
12 Company Analysis
13 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
Share this article